Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.21 USD
Change Today +0.01 / 0.83%
Volume 246.5K
As of 8:10 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (AVEO) Key Developments

AVEO Oncology Announces Exclusive Global License Agreement with Novartis

AVEO Oncology announced that the company sealed an exclusive global license agreement with Novartis (NVS), for the development and commercialization of AVEO's humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), the drug AV-380, and related antibodies or developments. AVEO announced that it will receive an upfront payment of $15 million and will be eligible to receive reimbursement, clinical, sales and regulatory-based milestone payments totaling $311 million. AVEO added it may receive tiered royalties. Novartis will be responsible for all clinical development, manufacturing and commercialization activities and costs associated with the drugs.

AVEO Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance

AVEO Pharmaceuticals, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported collaboration revenue of $134,000, loss from operations of $4,621,000, net loss of $5,456,000 or $0.1 compared to the collaboration revenue of $1,846,000, loss from operations of $17,465,000, net loss of $17,959,000 or $0.35 for the same quarter a year ago. For the six months period, the company reported collaboration revenue of $268,000, loss from operations of $14,770,000, net loss of $16,330,000 or $0.3 compared to the collaboration revenue of $17,135,000, loss from operations of $23,357,000, net loss of $24,409,000 or $0.47 for the same period a year ago. The company announced that cash resources will allow to fund current operations at least through the third quarter of 2016. This estimate does not include payment of potential licensing milestones or the costs of conducting any contemplated clinical trials and assumes no milestone payments from partners, additional funding from new partnership agreements, equity financings, debt financings or accelerated repayment thereof or further sales under ATM. The timing and nature of activities contemplated for 2015 and 2016 will be conducted subject to the availability of sufficient financial resources.

AVEO Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 10, 2015

AVEO Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 10, 2015

AVEO Oncology Announces Exclusive Licensing Agreement with Pharmstandard for Tivozanib in Russia, Ukraine and CIS

AVEO Oncology announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group for the development, manufacturing and commercialization of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. Under the terms of the agreement, Pharmstandard is obligated to pay AVEO an upfront payment of $1.5 million. AVEO is also eligible to receive up to $7.5 million in connection with the first marketing authorization of tivozanib in Russia, $3.0 million for each additional approved indication thereafter and a high single-digit royalty on net sales in the above mentioned territories. Pharmstandard will be responsible for all activities and costs associated with the further development, regulatory filings, health services and commercialization of tivozanib in the specified territories.

AVEO Pharmaceuticals, Inc. Approves Amendment to the Restated Certificate of Incorporation

AVEO Pharmaceuticals, Inc. announced at the AGM held on May 28, 2015, it has approved amendment to the company's restated certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVEO:US $1.21 USD +0.01

AVEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.99 USD -0.02
Bristol-Myers Squibb Co $59.88 USD -2.09
Exelixis Inc $5.78 USD -0.12
GlaxoSmithKline SAE £10.01 EGP 0.00
Takeda Pharmaceutical Co Ltd ¥5,479 JPY +52.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AVEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.7x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at